Drugs / palifosfamide-tris
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01340547 | Jun 2011 → Sep 2013 | cancer | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT01242072 | Nov 2010 → Dec 2012 | non-small cell lung carcinoma, osteosarcoma, ovarian cancer, small cell lung carcinoma +2 | Alaunos Therapeutics | Unknown | No outcome recorded |
| Phase 1 | NCT00607711 | Mar 2008 → Nov 2009 | — | Alaunos Therapeutics | Suspended | No outcome recorded |
| Phase 1 | NCT00608803 | Jan 2008 → Jan 2009 | cancer of unknown primary site | Alaunos Therapeutics | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01555710 | May 2012 → Jun 2015 | small cell lung carcinoma | Alaunos Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | palifosfamide-tris | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01242072 ↗ |
| Known as | ZIO-201-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00608803 ↗ |
| Modality | Other / unclassified | “Palifosfamide-tris, a novel DNA Crosslinker” NCT01555710 ↗ |
| Route | Oral | “oral palifosfamide tris capsules” NCT00607711 ↗ |